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Summary
(1) The AAGBI has published guidance on manage-
ment of anaphylaxis during anaesthesia in 1990,
1995 and 2003. This 2008 update was necessary to
disseminate new information.
(2) Death or permanent disability from anaphylaxis in
anaesthesia may be avoidable if the reaction is
recognised early and managed optimally.
(3) Recognition of anaphylaxis during anaesthesia is
usually delayed because key features such as hypo-
tension and bronchospasm more commonly have a
different cause.
(4) Initial management of anaphylaxis should follow the
ABC approach. Adrenaline (epinephrine) is the
most effective drug in anaphylaxis and should be
given as early as possible.
(5) If anaphylaxis is suspected during anaesthesia, it is
the anaesthetist’s responsibility to ensure the patient
is referred for investigation.
(6) Serum mast cell tryptase levels may help the
retrospective diagnosis of anaphylaxis: appropriate
blood samples should be sent for analysis.
(7) Specialist (allergist) knowledge is needed to inter-
pret investigations for anaesthetic anaphylaxis,
including sensitivity and speciﬁcity of each test
used. Specialist (anaesthetist) knowledge is needed
to recognise possible non-allergic causes for the
‘reaction’. Optimal investigation of suspected reac-
tions is therefore more likely with the collaboration
of both specialties.
(8) Details of specialist centres for the investigation of
suspected anaphylaxis during anaesthesia may be
found on the AAGBI website http://www.aagbi.
org.
(9) Cases of anaphylaxis occurring during anaesthesia
should be reported to the Medicines Control
Agency and the AAGBI National Anaesthetic
Anaphylaxis Database. Reports are more valuable
if the diagnosis is recorded following specialist
investigation of the reaction.
(10) This guidance recommends that all Departments
of Anaesthesia should identify a Consultant Anaes-
thetist who is Clinical Lead for anaesthetic
anaphylaxis.
Introduction
The AAGBI published its ﬁrst guidelines on suspected
anaphylactic reactions in 1990. Subsequent revisions were
published in 1995 and 2003. The current guidelines
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immunologists, allergists and anaesthetists throughout
the UK. In common with the 1995 and the 2003
editions, this report is published jointly with the British
Society for Allergy and Clinical Immunology (BSACI).
This document is intended to be concordant with, and
complementary to, the 2007 Scandinavian Clinical
Practice Guidelines, the 2008 Resuscitation Council
UK guidelines and the BSACI guidelines: Investigation
of suspected anaphylaxis during anaesthesia.
These guidelines apply only to suspected anaphylactic
reactions associated with anaesthesia and it is presupposed
that the patient is in the care of a trained anaesthetist.
Objectives
(1) To clarify the deﬁnitions used in allergy and
anaphylaxis.
(2) To review the epidemiology of anaesthesia-related
anaphylaxis.
(3) To provide advice on the recognition of anaesthetic
anaphylaxis.
(4) To make recommendations on the immediate man-
agement and initial investigation of suspected anaes-
thetic anaphylaxis.
(5) To make recommendations concerning the further
investigation of suspected anaesthetic anaphylaxis.
(6) To assist anaesthetists in obtaining access to a
specialist centre for comprehensive investigation of
suspected anaesthetic anaphylaxis.
(7) To assist anaesthetists to provide appropriate infor-
mation to the specialist centre.
(8) To make recommendations about the reporting and
collection of data on anaesthetic anaphylaxis in Great
Britain and Ireland.
Deﬁnitions
The term ‘anaphylaxis’ has been used for all types of acute
life-threatening illness triggered by abnormal sensitivity
(hypersensitivity) to a trigger agent, and for apparently
spontaneous attacks with similar features (idiopathic
anaphylaxis). This has made it difﬁcult to deﬁne. The
EAACI Nomenclature Committee proposed the follow-
ing broad deﬁnition [1]:
Anaphylaxis is a severe, life-threatening, generalized or
systemic hypersensitivity reaction.
Minor, localised or non-systemic reactions are outside
the deﬁnition of anaphylaxis. Anaphylaxis may be divided
into ‘allergic anaphylaxis’ and ‘non-allergic anaphylaxis’.
The clinical features of allergic anaphylaxis and non-
allergic anaphylaxis may be identical. The EAACI com-
mittee proposed the term ‘allergic anaphylaxis’ should be
used only when the reaction is mediated by an immuno-
logical mechanism (such as IgE, IgG, or complement
activation by immune complexes). An anaphylactic
reactionmediatedbyIgEantibodies,suchastoamoxicillin,
is referred to as ‘IgE-mediated allergic anaphylaxis’.
The term ‘anaphylactoid’ reaction had been introduced
for non-IgE-mediated anaphylactic reactions but the
EAACI committee has recommended this term should
no longer be used. This proposal has not been universally
accepted. An authoritative recent American practice
parameter [2] states: ‘Anaphylaxis is deﬁned … as a
condition caused by an IgE-mediated reaction [2].
Anaphylactoid reactions are deﬁned as those reactions
that produce the same clinical picture as anaphylaxis but
are not IgE mediated.’ In these guidelines we will follow
the European (EAACI) nomenclature.
Anaphylaxis is not a homogeneous process: the
pathways, mediators, time course and response to
treatment depend on the trigger agent, its route and
rate of administration, the nature of the patient’s
hypersensitivity and the state of health of the patient,
including incidental pathology such as respiratory or
cardiovascular disease and the effects of concomitant
medication such as b-blockers and ACE inhibitors.
Although anaphylaxis commonly involves respiratory,
cutaneous and circulatory changes, variations such as
shock with gastrointestinal disturbance or shock alone
are possible. Alternatively, reactions may be fatal
without signiﬁcant shock except as the terminal event
following respiratory arrest [3]. Angioedema and urti-
caria may be features of anaphylaxis but commonly
result from mechanisms other than anaphylaxis.
Intravascular volume redistribution is an important
component of anaphylactic shock. Cardiac output may
be decreased as a result of reduced coronary artery
perfusion pressure as well as impaired venous return.
Local release of mediators may cause coronary artery
spasm and there may be features of acute left or right
ventricular failure. Myocardial ischaemia with ECG
changes is expected within minutes of anaphylactic shock
becoming severe.
Asphyxia may be due to upper airway occlusion caused
by angioedema, or bronchospasm with mucus plugging of
the lower airways; the latter most commonly occurs in
patients taking daily treatment for asthma. Both these
processes may occur simultaneously in patients reacting to
foods, latex, b-lactam antibiotics or aspirin.
Anaphylaxis usually resolves in 2–8 h but secondary
pathology arising from the reaction or its treatment may
prolong this. Resolution is complete except when
cerebral hypoxia at the peak of the reaction has caused
signiﬁcant brain damage, or when disordered clotting
leads to bleeding.
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Epidemiology
Geographical variation
Most reports on anaesthesia-related anaphylaxis originate
from France, Australia, New Zealand and the United
Kingdom. Other case series have been described from
Scandinavia and the USA. The true incidence and their
associated morbidity and mortality remain poorly deﬁned.
Both the accuracy and completeness of reporting is not
optimal.
10% of anaesthesia-related reactions reported to the UK
Medicines Control Agency (MCA) were fatal. These data
should be interpreted with caution because it is likely that
many less-severe reactions are not reported [1]. Reactions
that are accepted as side-effects of certain drugs, for
instance, histaminergic reactions due to atracurium and
mivacurium, may be under-reported. During a time
period of over 6 years only 361 reactions were reported
to the MCA. In a 2-year period 789 reactions were
reported in France in a comparable population where
there is a well-established culture of reporting anaesthesia-
related reactions [2].
Based on studies in Australia and France, the incidence
of anaphylaxis during anaesthesia has been estimated at
between 1 in 10 000 and 20 000 [3, 4] The true
incidence of anaphylaxis during anaesthesia in the UK is
not known. By extrapolating the French and Australian
data to the UK, it is estimated that there are approxi-
mately 500 severe reactions in the UK each year.
Anaphylactic reactions are more common when drugs
are given intravenously.
In one large study an immune basis was demonstrated
in two-thirds of patients investigated for anaphylaxis [2]:
the remainder comprised non-allergic anaphylaxis and
mechanisms other than anaphylaxis. The tests currently
available for the diagnosis of anaesthetic anaphylaxis are
imperfect. Skin tests and blood tests have limited
sensitivity and speciﬁcity and their positive and negative
predictive value varies between drugs.
Patient characteristics (age, sex, ethnicity,
smoking etc)
Neuromuscular blocking drugs and latex appear to cause
anaphylaxis more commonly in female patients. There
appears to be a connection between smoking and
antibiotic anaphylaxis, possibly because smokers may
become sensitised by exposure to repeated courses of
antibiotics for respiratory tract infections. Individuals with
a history of atopy, asthma or allergy to some foods appear
to be at increased risk of latex allergy but not anaphylaxis
to neuromuscular blocking drugs or antibiotics [2, 5].
Anaphylaxis associated with radiographic contrast media
appears to be associated with atopy [6]. Patients with
asthma or taking b-blocking drugs may suffer a more
severe reaction. Some of these reactions may be refractory
to conventional therapy.
Possible environmental sensitising agents
Theprevalenceofanaphylacticreactionstoneuromuscular
blockingagents(NMBAs)isreportedtobeatleastsixtimes
more frequent in some countries [7, 8]: it is considerably
more common in Norway than in Sweden. Quaternary
ammonium ions (QAI) are proposed to be the allergenic
epitopes in NMBAs. Common environmental chemicals
such as toothpastes, washing detergents, shampoos, and
cough medicines share these allergenic epitopes with the
NMBAs [8]. Numerous possibilities exist for a predisposed
individual to become sensitised to QAIs and thus be at risk
of developing anaphylaxis to NMBAs during anaesthesia.
In a recent Scandinavian survey, use of certain cough
medicineswasfoundtobetheonlysigniﬁcantdifferencein
environmental chemical exposure [8]. In Norway, but not
Sweden, cough syrups containing pholcodine are available
without prescription. IgE-antibodies to pholcodine were
seen in 6% of a general population (blood donors) in
Norway but not in Sweden (0%).
Muscle relaxants
Approximately 60% of cases of anaesthesia-related ana-
phylaxis are thought on the basis of skin tests to be due to
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curium are associated with non-allergic anaphylaxis in
which release of mediators (notably histamine) from mast
cells exactly imitates allergic anaphylaxis. Cisatracurium,
although sharing a benzylisoquinolinium structure, is not
associated with non-allergic anaphylaxis, although several
cases of allergic anaphylaxis have been reported. It is
generally accepted that succinylcholine is the NMBA
most likely to be associated with allergic anaphylaxis,
although rocuronium has been implicated in a similar
number of cases in France.
The prevalence of sensitisation to NMBAs in the
community is higher than the incidence of reactions
would suggest. In one study, approaching 10% of the
general population exhibited skin reactivity to NMBAs,
an incidence that far exceeds the incidence of anaphy-
laxis on administration of these drugs during anaesthesia
[9]. A previous history of speciﬁc drug exposure is
not necessary, particularly for neuromuscular blocking
drugs. A history of previous exposure is found in fewer
than 50% of patients who are allergic to neuromuscular
blocking drugs. Conversely, an uneventful exposure
may sensitise an individual to subsequent administration
of the drug.
Cross-sensitivity between different NMBAs is relatively
common, probably because they share a quaternary
ammonium epitope. If anaphylaxis to an NMBA is
suspected, the patient should undergo skin prick testing
with all the NMBAs in current use. If a patient demon-
strates a positive skin prick test (SPT) to an NMBA, the
patient should be warned against future exposure to all
NMBAs if possible. If it is mandatory to use an NMBA
during anaesthesia in the future, it would seem appropriate
to permit the use of an NMBA which has a negative skin
test, accepting that a negative skin test does not guarantee
that anaphylaxis will not occur.
The apparent excess of cases of anaphylaxis to rocu-
ronium in some countries should be interpreted with
caution until much more data have been collected. Large
sample sizes are needed to estimate the true incidence: if
the true incidence is 1 in 5000, a sample size of 7 million
would be needed to have a 95% chance of being within
5% of the true value [10]. There is a need for further
epidemiological studies.
Latex
Latex hypersensitivity is the second most common cause
of anaesthesia-related anaphylaxis in many studies (up to
20% of cases). However, the incidence of anaphylaxis to
latex is considerably less than would be suggested by the
prevalence of positive skin tests or positive IgE tests. It
appears that the incidence may be waning, at least in some
countries; possibly as a result of a change or decline in the
use of latex gloves. Certain patient groups are more
susceptible to latex anaphylaxis (see Appendix II).
Antibiotics
Approximately 15% of anaesthesia-related anaphylactic
episodes are due to antibiotics. This proportion has
increased in recent years and may merely mirror increased
exposure to antibiotics in the community [2, 11]. The
pre-operative history is important. Although only a
minority of patients who report allergy to antibiotics
have a true allergy, the consequence of anaphylaxis to
intravenous antibiotics may be catastrophic, and self-
reporting should be taken seriously. Skin testing is only
approximately 60% predictive of clinical hypersensitivity.
Penicillins and cephalosporins which share the b-lactam
ring are responsible for approximately 70% of antibiotic-
induced anaphylaxis. Many antibiotics possess a b-lactam
ring:
• Benzylpenicillin, phenoxymethylpenicillin
• Flucloxacillin, temocillin
• Amoxicillin, ampicillin, co-amoxiclav
• Co-ﬂuampicil
• Piperacillin, ticarcillin,
• Pivmecillinam HCl
• Cephalosporins
• Aztreonam
• Ertapenem, imipenem with cilastatin, meropenem
The structure of the side chains attached to the
b-lactam ring is also important in determining the
response of the immune system. First generation ceph-
alosporins and cefamandole share a similar side chain with
penicillin and amoxicillin. A recent meta-analysis sug-
gested that patients who are allergic to penicillin or
amoxicillin have a higher incidence of allergic reactions to
ﬁrst generation cephalosporins and cefamandole, but not
other cephalosporins [12]. The issue is complicated
because the classiﬁcation of cephalosporins relates to
their antimicrobial activity rather than their chemical
structure.
First generation cephalosporins
• Cefalexin (cephalexin)*
• Cephaloridine
• Cephalothin
• Cefazolin
• Cefradine (cephradine)*
• Cefadroxil *
Second generation cephalosporins
• Cefaclor*
• Cefamandole
• Cefuroxime*
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• Ceﬁxime*
• Cefotaxime*
• Cefpodoxime*
• Ceftazidime*
• Ceftriaxone*
Fourth generation cephalosporins
• Cefepime
• Cefpirome
*Listed in the British National Formulary.
Local anaesthetics
Anaphylactic reactions to local anaesthetic drugs are very
uncommon. Local anaesthetic esters are more likely than
amides to provoke a Type lV allergic reaction. Preserva-
tives such as methyl-paraben or metabisulphites may be
responsible in some cases. It has been suggested that
inadvertent intravascular injection of a local anaesthetic or
the systemic absorption of adrenaline may be responsible
for many of the reported reactions. Reactions occurring
in the dental chair may also be associated with idiopathic
angioedema or latex allergy.
Opioids
Opioids are an uncommon cause of anaesthesia-related
anaphylaxis. Diagnosis is difﬁcult and the true incidence is
unknown. Morphine, pethidine and codeine are well-
known to cause non-speciﬁc histamine release which
precludes diagnostic skin testing. The diagnosis of opioid
anaphylaxis often rests on a careful history and the
exclusion of other possibilities. Challenge testing may be
appropriate in some cases but may be performed only in
specialist centres.
Anaesthetic induction agents
Anaphylaxis to propofol is very uncommon. The antigenic
determinantmaybetheisopropylgroups.Ithasbeenstated
that patients with egg allergy or soy allergy should avoid
propofol but there is no strongly-supportive evidence. It
has been suggested that propofol anaphylaxis is more likely
if lignocaine is added to reduce pain on injection: there is
no evidence to support this suggestion. Anaphylaxis to
thiopental has become extremely uncommon, probably
reﬂecting the decline in its use. A small number of cases of
midazolam anaphylaxis have been reported.
Non-steroidal anti-inﬂammatory drugs (NSAIDs)
Several mechanisms may be responsible for reactions
to NSAIDs. Inhibition of the PGE2 pathway leads to
excessive leukotriene synthesis and subsequent mediator
release, causing urticaria or bronchospasm. IgE-mediated
reactions may also occur in relation to some NSAIDs.
Fatal anaphylaxis has been described after oral adminis-
tration of NSAIDs.
Halogenated volatile anaesthetics
There are no published reports of anaphylaxis to
halogenated volatile anaesthetics. The rare fulminant
form of hepatitis associated with halothane has an
immune basis which is unrelated to anaphylaxis.
Colloids
Intravenous colloids are responsible for approximately 4%
of all peri-operative anaphylactic reactions. In one study,
gelatin solutions were responsible for 95% of the intra-
venous colloid reactions. It has been stated that the
incidence may be greater with the urea-linked gelatins
compared with the modiﬁed ﬂuid gelatins. Intravenous
gelatin solutions should be avoided in patients with a
history of allergy to gelatin-containing vaccines. Ana-
phylaxis to intravenous dextrans has been reported, with
an incidence similar to the modiﬁed ﬂuid gelatins.
Anaphylaxis to hydroxyethyl-starch is rare.
Antiseptics and disinfectants
Reactions to chlorhexidine have come into greater
prominence in recent years. There appears to be a
signiﬁcant difference in incidence between countries [13].
Reactions range from contact dermatitis to life-threaten-
ing anaphylaxis. Anaphylaxis has occurred when chlor-
hexidine was used as an antiseptic for urological and
gynaecological procedures as well as insertion of central
venous and epidural catheters. The chlorhexidine coating
of certain central venous catheters has been implicated in
such reactions. It is prudent to allow skin disinfectant to
completely dry before beginning an invasive procedure.
Anaphylaxis to polyvinylpyrrholidine as povidone-iodine
or as an excipient for oral medicines occurs but is rare.
Miscellaneous agents
Many agents to which patients may be exposed during
anaesthesia may be associated with anaphylaxis, including
aprotinin, protamine, heparins, radiological contrast
material, dyes and oxytocin. Anaphylaxis to glycopyrro-
nium and neostigmine may occur very rarely.
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Recognition and clinical diagnosis of anaphylaxis
In a closely monitored patient such as during anaesthesia,
when a fall in blood pressure, change in heart rate or
difﬁculty with ventilation are noticed, anaphylaxis is so
rarely the cause that inevitably treatment is given for
another diagnosis before anaphylaxis is recognised; the
response to this treatment has commonly delayed or even
prevented recognition of the true cause. It is therefore
probable that many grade I and II acute allergic reactions
to anaesthetic drugs are missed. Conversely, a cause other
than allergic anaphylaxis seems more likely in around
one-third of the patients referred to specialist centres for
investigation of suspected anaphylaxis during anaesthesia.
Previous history
Any clue that appropriately raises anticipation of anaphy-
laxis will be helpful. A previous history of reaction to
anaesthetic drugs, antibiotics, other drugs, chlorhexidine
or latex should obviously lead to appropriate avoidance.
Because it is always possible the wrong trigger factor
was identiﬁed, the exact details of exposure leading to
any previous reaction should be sought during the
pre-operative assessment. Cross-reactivity between non-
anaesthetic drugs such as pholcodine or environmental
chemicals containing quaternary ammonium groups such
as cosmetics and detergents has been proposed as the
source of sensitivity to opioids and muscle relaxants: a
history of cutaneous sensitivity to cosmetics or rashes
from cough medicines should raise caution.
Anaphylaxis to amoxicillin and cephalosporins is
commonest in asthmatic smokers who have had
multiple courses of these antibiotics without reacting:
the symptoms of anaphylaxis in such a patient are likely
to be initially misinterpreted (quite reasonably) as those
expected from anaesthesia in an asthmatic smoker.
Clinical features
Although anaesthesia-related anaphylaxis usually results
from intravenous drug administration, administration by
other routes, for example cutaneous, mucosal ⁄vesical
peritoneal, intra-articular or intramuscular may be respon-
sible. Clinical features include hypotension, tachycardia or
bradycardia; cutaneous ﬂushing, rash or urticaria; bron-
chospasm; hypoxia; angioedema and cardiac arrest. If an
adverseeventsuchashypotension orbronchospasm occurs
during anaesthesia it is appropriate to suspect anaphylaxis
unless there exists a signiﬁcantly more likely cause.
Tachycardia is not invariable: bradycardia is seen in
approximately 10% of patients with allergic anaphylaxis
during anaesthesia. Hypotension is the sole clinical feature
in approximately 10% of patients and is likely to be
exaggerated in patients undergoing anaesthesia with neur-
axial blockade. Widespread ﬂushing or urticaria is seen in
the majority of patients but the absence of cutaneous signs
does not exclude anaphylaxis. Bronchospasm may be more
common in patients with pre-existing asthma.
Clinical features
Allergic
anaphylaxis
(n = 518), n (%)
Non-allergic
anaphylaxis
(n = 271), n (%)
Cardiovascular 387 (74.7) 92 (33.9)
Arterial hypotension 90 (17.3) 50 (18.4)
Cardiovascular collapse 264 (50.8) 30 (11.1)
Bradycardia 7 (1.3) 2 (0.7)
Cardiac arrest 31 (5.9) –
Bronchospasm 207 (39.8) 52 (19.2)
Cutaneous signs 374 (71.9) 254 (93.7)
Angioedema 64 (12.3) 21 (7.7)
Clinical features of allergic anaphylaxis and non-allergic anaphylaxis
occurring during anaesthesia in France between 1st Jan 1999 and 31st
Dec 2000. Mertes PM et al. Anesthesiology 2003; 99: 536–45.
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butmaybedelayedbyuptoanhour.Substancestowhichthe
clinical reaction may be delayed include latex, antibiotics,
intravenous colloids and Cidex OPA (used to disinfect
surgicalinstruments).However,animmediateresponsedoes
not exonerate these substances. The clinical features of
anaphylaxis to neuromuscular blocking agents usually
develop rapidly. Deﬂation of a surgical tourniquet may
induceanaphylaxisiftheallergenhasbeensequesteredinthe
limb.
Immediate management
These management guidelines presuppose that the patient is in
the care of an appropriately-trained anaesthetist and full
resuscitation facilities and appropriate vital signs monitors are
available.
There is a wide spectrum of severity and combinations
of clinical features. Although management should be
tailored to the individual patient, there is consensus that
adrenaline should be given as early as possible. In addition
to having alpha-agonist activity, adrenaline is a valuable
beta-agonist which is inotropic and a bronchodilator, and
reduces further mediator release.
Other causes of hypotension or difﬁculty in ventilation
should be excluded, for example a misplaced tracheal tube
or equipment failure.
Immediate management
1 Use the ABC approach (Airway, Breathing, Circu-
lation). Team-working enables several tasks to be
accomplished simultaneously.
2 Remove all potential causative agents (including IV
colloids, latex and chlorhexidine) and maintain anaes-
thesia, if necessary, with an inhalational agent.
3 Call for help and note the time.
4 Maintain the airway and administer oxygen 100%.
Intubate the trachea if necessary and ventilate the lungs
with oxygen.
5 Elevate the patient’s legs if there is hypotension.
6 If appropriate, start cardiopulmonary resuscitation
immediately according to Advanced Life Support
Guidelines.
7 Administer adrenaline intravenously. An initial dose of
50 lg (0.5 ml of 1 : 10 000 solution) is appropriate
(adult dose). Several doses may be required if there is
severe hypotension or bronchospasm.
8 If several doses of adrenaline are required, consider
starting an intravenous infusion of adrenaline (adren-
aline has a short half-life).
9 Administer saline 0.9% or lactated Ringer’s solution at
a high rate via an intravenous cannula of an appropriate
gauge (large volumes may be required).
Secondary management
1 Administer chlorphenamine 10 mg IV (adult dose).
2 Administer hydrocortisone 200 mg IV (adult dose).
3 If the blood pressure does not recover despite an
adrenaline infusion, consider the administration of an
alternative intravenous vasopressor according to the
training and experience of the anaesthetist, for example
metaraminol.
4 Treat persistent bronchospasm with an intravenous
infusion of salbutamol. If a suitable breathing-system
connector is available, a metered-dose inhaler may be
appropriate. Consider giving intravenous aminophyl-
line or magnesium sulphate.
5 Arrange transfer of the patient to an appropriate Critical
Care area.
6 Take blood samples (5–10 ml clotted blood) for Mast
Cell Tryptase as follows:
a Initial sample as soon as feasible after resuscitation has
started – do not delay resuscitation to take the sample.
b Second sample at 1–2 h after the start of symptoms.
c Third sample either at 24 h or in convalescence (for
example in a follow-up allergy clinic). This is a
measure of baseline tryptase levels as some individuals
have a higher baseline level.
d Ensure that the samples are labelled with the time
and date.
7 Liaise with the hospital laboratory (see Appendix lll:
Mast cell Tryptase).
Drug doses in children
Adrenaline
Intramuscular
> 12 years: 500 lg IM (0.5 ml of a 1 : 1000 solution)
300 lg IM (0.3 ml of a 1 : 1000 solution) if the child is
small
6–12 years: 300 lg IM (0.3 ml of a 1 : 1000 solution)
Up to 6 years: 150 lg IM (0.15 ml of a 1 : 1000
solution)
Intravenous
Intravenous adrenaline may be used in children in acute
areas such as operating theatres or intensive care units by
those familiar with its use and if IV access is already
available. Great care should be taken to avoid dose errors
when preparing drug dilutions. Prepare a syringe con-
taining 1 ml of 1 : 10 000 adrenaline for each 10 kg body
weight (0.1 ml.kg
)1 of 1 : 10 000 adrenaline solution =
10 lg.kg
)1. Titrate to response, starting with a dose of
one-tenth of the contents of the syringe, i.e. 1 lg.kg
)1.
Often a child will respond to as little as 1 lg.kg
)1.I n
smaller children, further dilution may be needed to allow
dose titration (check carefully for decimal point and
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ferred where there is no venous access or where
establishing venous access would cause a delay in drug
administration.
Hydrocortisone
> 12 years: 200 mg IM or IV slowly
6 to 12 years: 100 mg IM or IV slowly
6 months to 6 years: 50 mg IM or IV slowly
< 6 months: 25 mg IM or IV slowly
Chlorphenamine
> 12 years: 10 mg IM or IV slowly
6 to 12 years: 5 mg IM or IV slowly
6 months to 6 years: 2.5 mg IM or IV slowly
< 6 months: 250 lg.kg
)1 IM or IV slowly
Later investigations to identify the causative
agent
Any patient who has a suspected anaphylactic reaction
associated with anaesthesia should be investigated fully,
but investigations should not interfere with the immediate
treatment of the patient. The anaesthetist who adminis-
tered the anaesthetic or the consultant anaesthetist in
charge of the patient is responsible for ensuring that the
reaction is investigated.
The patient should be referred to a specialist Allergy or
Immunology centre that has appropriate experience of
investigating this type of problem. Anaesthetic departments
should identify a lead anaesthetist for anaesthetic anaphylaxis.
Referral pathways should be agreed prospectively with the
appropriate specialist centre.
Criteria for referral to a specialist centre
for investigation
Patients in whom allergic or non-allergic anaphylaxis is
suspected should be referred to a specialist clinic for
investigation. A patient should be referred if there is any
of the following:
1 Unexplained cardiac arrest during anaesthesia.
2 Unexplained, unexpected hypotension (for example
a decrease of mean arterial pressure of more than
30 mmHg) which requires active treatment.
3 Unexplained, unexpected bronchospasm, particularly if
the bronchospasm is severe, causes a signiﬁcant decrease
in oxygen saturation and is relatively resistant to
treatment.
4 Widespread rash, ﬂushing or urticaria.
5 Angioedema.
A detailed analysis of events surrounding the suspected
anaphylactic reaction must be undertaken. The time of
onset of the reaction in relation to induction and other
events is the most important information. All drugs and
other agents to which the patient was exposed before and
during the anaesthetic as well as their timing in relation to
the reaction must be recorded.
Details sent to the specialist centre along with a letter of
referral must include:
• A legible photocopy of the anaesthetic record
• A legible photocopy of the recovery room chart
• Legible photocopies of drug charts
• A description of the reaction and time of onset in
relation to induction
• Details of blood tests sent and their timing in relation to
the reaction
• Contact details of the surgeon and the general practi-
tioner
A standard referral proforma is useful (see Appendix S1 in
Supporting Information).
Tests performed at the specialist centre
Skin tests
Patients should be referred for skin testing as soon as
possible after the clinical event. Skin testing can be
performed as soon as the patient has made a full clinical
recovery and the effects of any antihistamine given to
treat the reaction have fully worn off. Skin tests can
provide conﬁrmation of sensitisation to a speciﬁc drug but
must be interpreted within the clinical context. There are
a variety of techniques and several different criteria are
used for positivity [1–4] so skin testing must be performed
by suitably trained and experienced personnel.
A histamine solution and physiological saline are used
as positive and negative controls respectively. Drugs with
anti-histamine activity must be discontinued a few days
before testing. There is no need to discontinue oral or
inhaled steroids.
Skin prick tests are usually done on the volar surface of
the forearm. A drop of the drug is placed on the skin and
the skin pricked through the drop with a lancet. The
results are read after 15–20 min.
Intradermal tests may be performed where skin prick
tests are negative. Although they are more sensitive, they
are less speciﬁc, more difﬁcult to interpret and more likely
to precipitate a systemic reaction. Intradermal tests are
usually performed on the forearm or back. 0.02 to
0.05 ml of a dilute solution is injected intradermally and
the results read after 20–30 min.
Both skin prick tests and intradermal tests are widely
used in the diagnosis of IgE mediated allergic reactions
though the diagnostic value of a positive test for most
drugs is limited due to lack of subsequent challenge data.
If the mechanism is unknown a negative test is unreliable.
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lists of non-irritant dilutions have been compiled for
both skin prick tests and intradermal tests [5]. Skin tests
are most useful for latex, beta lactam antibiotics and
NMBAs. They are also useful for induction agents,
protamine [6] and chlorhexidine. Intradermal testing
may be more reliable for propofol [2]. Skin tests are not
usually performed for opioids because false positive
results are common. However, skin prick testing appears
to be informative for the synthetic opioids fentanyl and
remifentanil. Skin tests are not useful for NSAIDs,
dextrans or iodinated radiological contrast media [6]
because anaphylaxis to these agents is not usually
IgE-mediated.
Patch tests are the mainstay of diagnosis for contact
allergic reactions and may be useful for diagnosing
exanthematous drug rashes but are not helpful in eliciting
the cause of suspected anaphylactic reactions occurring
during anaesthesia.
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Blood tests
Appropriate further blood investigations depend on the
drug in question, and the experience of the specialised
laboratory service. Blood samples for speciﬁc IgE tests
may be taken at the time of the reaction, or soon
afterwards during that hospital admission. If the results are
negative these tests should be repeated when the patient is
seen at the specialist centre in case the initial results might
be falsely negative due to possible consumption of
relevant IgE antibodies during the reaction. The most
commonly used test for allergen-speciﬁc IgE uses target
allergen or drug bound onto a three-dimensional sponge-
like solid matrix or ‘CAP’ and a ﬂuorescent detection
system. The Radio-AllergoSorbent Test (RAST) uses a
radioactive detection system: it is now rarely used but the
name has persisted in common use.
Speciﬁc IgE antibodies against succinylcholine (thio-
choline ester) can be assayed in serum but the sensitivity is
relatively poor (30–60%). Tests for serum IgE antibodies
against other neuromuscular blocking drugs are not
available in the UK. Speciﬁc IgE antibodies against
several antibiotics can be assayed. These include amox-
icilloyl, ampicilloyl, penicilloyl G, penicilloyl V and
cefaclor, however the diagnostic value of these tests is less
well deﬁned. Tests for speciﬁc antibodies against latex,
chlorhexidine and bovine gelatin are available.
The presence of drug-speciﬁc IgE in serum is evidence
of allergic sensitisation in that individual and provides a
possible explanation of the mechanism and speciﬁc drug
responsible for the reaction. It is not in itself proof that
the drug is responsible for the reaction. It is important
to emphasise that attribution of cause and effect is a
judgement made after considering all the clinical and
laboratory information relevant to the reaction.
Experimental tests
There is much research into ways of improving the in
vitro elucidation of anaphylaxis. In addition to tissue-
bound mast cells, circulating basophils are also involved in
anaphylaxis. During anaphylaxis, proteins such as CD63
and CD203c become newly or increasingly expressed on
the surface of basophils. These can be detected by ﬂow
cytometry which forms the basis of experimental drug-
induced basophil stimulation tests.
Appendix I
Frequently asked questions
Should I give a test dose of IV antibiotic?
No. Predictive testing would require serial challenges with
increasing doses, starting with a minuscule dose and allow-
ing at least 30 min between each dose. This approach is
impossible within the constraints of an operating list.
Should I avoid cephalosporins in a patient who gives a history
suggestive of penicillin allergy?
Mostpatients whogive ahistoryof apenicillin-related rash
are not allergic to cephalosporins. However, there are now
many suitable alternatives to cephalosporins and, unless
there are compelling bacteriological indications, it would
be appropriate to consider avoiding ﬁrst and second
generation cephalosporins. If there is a convincing history
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and second generation cephalosporins is stronger.
Should I use crystalloid or colloid in the immediate management
of anaphylaxis?
There is no evidence that one is better than the other.
If an IV colloid has already been given to the patient
before the appearance of clinical signs of anaphylaxis, it
should be discontinued and either replaced by crystal-
loid or replaced by a colloid of a different class; e.g.
replace a gelatin-based colloid with a starch-based
colloid.
Should I give an H2-blocking drug as part of the immediate
management of anaphylaxis?
There is no evidence to support the use of H2-blocking
drugs in this situation.
What should I do if a patient with a convincing history of cardio-
respiratory collapse during a previous anaesthetic presents for
emergency surgery without having been investigated for
anaphylaxis?
1 Covert cardiac or respiratory disease should be
sought in accordance with normal pre-operative
practice.
2 It may be possible to exclude latex allergy by taking a
detailed history from the patient. If this is impossible, a
latex-free environment should be provided.
3 Inhalational agents are likely to be safe unless the
previous collapse was due to malignant hyperthermia.
4 If previous records are available:
a It would be appropriate to avoid all drugs given
during the previous anaesthetic before the onset of
cardio-respiratory collapse, with the exception of
inhalational agents.
b If the patient received a neuromuscular blocking
drug before the collapse, then all neuromuscular
blocking drugs should be avoided if possible because
cross-sensitivity is common.
5 If previous records are not available:
a It would be appropriate to avoid all neuromuscular
blocking drugs if possible (the anaesthetist will need
to assess the balance of risks).
b Drugs used in local and regional anaesthesia are likely
to be safe; allergy to amide local anaesthetic drugs is
extremely rare.
c It would be appropriate to avoid chlorhexidine
preparations if possible; allergy to povidone iodine is
less common than allergy to chlorhexidine.
d The previous reaction may have been the result of
non-allergic anaphylaxis; it would be appropriate to
avoid drugs that are known to release histamine, for
example morphine.
6 There is no evidence that pre-treatment with hydro-
cortisone or histamine-blocking drugs will reduce the
severity of anaphylaxis.
What should I say to a patient who wishes to be screened for
anaesthetic allergy pre-operatively?
Unless there is a history suggestive of previous anaesthetic
anaphylaxis, pre-operative screening is of no value. The
sensitivity and speciﬁcity of skin tests and blood tests is
relatively low. If the pretest probability is very low, i.e.
there is no positive history, neither a negative test nor a
positive test is likely to be predictive of outcome.
Should I avoid propofol in patients who are allergic to eggs, soya or
nuts?
There is no published evidence indicating that propofol
should be avoided in patients who are allergic to eggs,
soya or nuts. Propofol contains puriﬁed egg phosphatide
and soya-bean oil. It is likely that the manufacturing
process removes or denatures the proteins responsible for
egg allergy and soya allergy. However, a cautious
approach would seem to be appropriate in patients with
egg allergy or soya allergy.
I don’t have a specialist allergy centre nearby. Should I do my
own skin-testing?
The results of skin tests are very technique-dependent and
their interpretation requires specialist training and expe-
rience.
Appendix II
Latex allergy
Latex is a natural rubber derived from the sap of a tree
(Hevea brasiliensis) found in Asia which contains several
water-soluble proteins, designated Hev b 1- Hev b 13.
Patient contact with natural rubber latex (NRL) during
anaesthesia may occur via several routes including the
airway, mucous membranes, surgical wounds and par-
enteral injection. An anaphylactic reaction to NRL
during anaesthesia may be immediate, or may be
delayed for up to an hour. The clinical manifestations
of NRL anaphylaxis during anaesthesia tend to be less
severe than anaphylaxis due to neuromuscular blocking
drugs.
Classiﬁcation of latex reactions
1 Systemic reaction: a Type 1 hypersensitivity reaction
involving speciﬁc IgE to Hev proteins, mostly to Hev b
5&6. This is the most severe but least frequent reaction
and occurs in genetically predisposed individuals. The
symptoms consist of itching, swelling, rhinitis, asthma
and anaphylaxis. This allergy is life long. A proportion
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reacting with latex proteins.
2 Contact dermatitis: a delayed Type IV hypersensitivity
reaction consisting of an eczematous reaction starting
24–48 h after repeated skin or mucosal contact with
additives used during rubber production. This is a
T cell-mediated, non-life-threatening reaction. It may,
however, predispose the individual to a more severe
systemic reaction.
3 Clinical non-immune-mediated reaction: irritant der-
matitis resulting from a mild irritant effect of the
powder in the gloves and that of disinfectants, sweating
etc. This is the most frequent reaction, is limited to the
contact area and is characterised by itching, irritation
and blistering at the side of contact.
High risk individuals
Approximately 8% of the population is sensitized to latex
but only 1.4% of the population exhibits latex allergy.
The following groups are at increased risk:
• Patients with atopy
• Children undergoing multiple surgical procedures,
such as spina biﬁda, or children undergoing surgery at
a very young age
• Patients with severe dermatitis of their hands
• Healthcare professionals
• Patients with allergy to fruits; most frequently banana,
chestnut and avocado
• Industrial workers using protective gear
• Occupational exposure to latex
Pre-operative assessment
A history of pre-operative symptoms suggestive of latex
allergy is present in approximately a quarter of patients
who develop intra-operative NRL anaphylaxis. A thor-
ough history, including an occupational history, should
be part of the pre-operative assessment. It is useful to ask
speciﬁcally whether contact with balloons, condoms or
latex gloves provokes itching, rash or angioedema.
Pre-operative testing
If the clinical history is positive or equivocal, the patient
should be referred for testing before the surgical proce-
dure and surgery should proceed only in an emergency.
In the preoperative situation, it is particularly important
to exclude IgE-mediated sensitivity. The choice of test:
either a blood test for latex-speciﬁc IgE, or skin testing
may depend on local availability. Current tests have a
sensitivity of approximately 75–90%; skin prick testing
may be more sensitive than blood tests for speciﬁc IgE. It
is important that skin prick tests are performed by trained
staff. It may be appropriate to proceed to challenge testing
in some patients.
Peri-operative precautions
• If NRL allergy is diagnosed pre-operatively, avoidance
is mandatory.
• Care should be taken to avoid introducing additional,
unrelated hazards when latex precautions are imple-
mented in the operating theatre.
• Latex allergy should be recorded in the case-notes and
on the patient’s wrist bracelet.
• The surgical team and the nursing and anaesthetic
support teams should be alerted.
• There is no evidence that premedication with an anti-
histamine or steroid is useful.
• The operating theatre should be prepared the night
before to avoid the release of latex particles and the
patient should be scheduled ﬁrst on the list. Evidence is
limited regarding the need for this degree of caution in
operating theatres where all latex gloves are of the non-
powdered type.
• A ‘Latex allergy’ notice should be placed on the doors
to the anaesthetic room and operating theatre.
• Staff trafﬁc should be limited.
• Absolute use of synthetic gloves when preparing
equipment and during anaesthesia, surgery and post-
operative care.
• Non-essential equipment should be removed from the
vicinity of the patient.
• The anaesthetic and surgical areas must contain only
latex free products.
• Only latex-free dressings and tapes should be applied.
• Equipment in resuscitation boxes and trolleys must
contain only latex free material.
Postoperative investigation of possible latex anaphylaxis
If skin testing and speciﬁc IgE testing is negative or
equivocal in the presence of a suggestive history, it may
be appropriate for the patient to proceed to a provocation
test with the ﬁnger of a latex glove. This procedure must
be performed by trained staff and resuscitation facilities
must be available. Patch testing by an expert is useful in
the diagnosis of delayed (Type lV) hypersensitivity to
rubber.
Hospital Latex-Allergy Policy
It is recommended that all hospitals have a latex-allergy
policy which should address the following:
• A named clinical lead for latex allergy
• Instructions for accessing latex-allergy testing
• Latex allergy precautions in the ward and clinic settings
• Latex allergy precautions in the operating theatre
environment
• Avoidance of latex sensitization in employees
• Liaison with pharmacy and equipment-procurement
departments
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Appendix III
Mast cell tryptase
1 Mast cells are found within many tissues including
lung, intestine and skin. Tryptase is a protease
enzyme which acts via widespread protease activated
receptors (PARs). There are two types of tryptase; a
and b, each of which has several subtypes. Mature
b-tryptase is stored in granules in mast cells and is
released during anaphylaxis by a calcium-dependent
mechanism. a-tryptase is secreted constitutively by
mast cells and is the form normally found in the
blood in health. a-tryptase is elevated in systemic
mastocytosis. Pro-b-tryptase is also secreted consti-
tutively by mast cells.
2 The normal functions of tryptase include modulation
of intracellular calcium ion and intestinal chloride ion
transportinadditionto mediatingrelaxation of smooth
muscle in vascular endothelium and bronchial smooth
muscle. In inﬂammation, tryptase stimulates the release
of pro-inﬂammatory interleukins and stimulates fur-
ther tryptase secretion by neighbouring mast cells.
3 A variety of pathways may combine to produce
anaphylaxis, depending on the trigger and the suscep-
tibility of the patient. Typically anaphylaxis results
from mast cell activation, and typically this will cause
release of mast cell b-tryptase into the circulation.
4 Anaphylaxis may be caused by basophil or comple-
ment activation, both of which are not associated with
a rise in mast cell tryptase. A raised tryptase concen-
tration is therefore a marker of anaphylaxis, but
anaphylaxis does not always cause a raised concentra-
tion. The greater the rise in concentration, the greater
the probability this was caused by an anaphylactic
reaction but a normal concentration does not disprove
anaphylaxis.
5 A rise in serum tryptase simply indicates mast cell
degranulation and does not discriminate between
allergic and non-allergic anaphylaxis. It has been
stated that the rise in serum tryptase concentration
may be less marked in non-allergic anaphylaxis.
6 During anaphylaxis, tryptase peaks by approximately
1 h and its half-life in the circulation is about 2 h: the
concentration therefore falls rapidly following an
anaphylactic reaction.
7 ThemostwidelyusedassayfortryptaseistheImmuno-
CAP
  ﬂuorescence enzyme immunoassay (FEIA)
which measures the sum of a and b-tryptase concen-
trations. Araisedresting concentration is usuallydueto
a-tryptase, secreted constitutively by the increased
numbers of mast cells in systemic mastocytosis.
8 Although the current tryptase assay has a high
speciﬁcity, its sensitivity is relatively low and some
cases of anaphylaxis may be missed.
9 The sensitivity and speciﬁcity of the tryptase assay
depends on the cut-off point that is chosen to indicate
anaphylaxis. Because there is a wide variation in the
base-line plasma concentration of tryptase, the change
in tryptase concentration is more helpful than the
absolute concentration in reaching a diagnosis.
10 Intravenous ﬂuid replacement is usually required
during treatment of a reaction. This ﬂuid will dilute
the blood and causes a fall in the concentration of
tryptase measured. This must be taken into account
when evaluating the measured concentration.
11 Following death, the circulation stops and tryptase is no
longer removed from the circulation; samples taken
postmortemarehelpfulinevaluatingwhetherthetermi-
nal events were related to anaphylaxis. A raised tryptase
concentration found at autopsy has lower predictive
value than a sample taken during life. b-tryptase may be
raised in trauma or myocardial infarction.
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Useful websites
http://www.aagbi.org
The Association of Anaesthetists of Great Britain and
Ireland
http://www.bsaci.org
The British Society for Allergy and Clinical Immunology
http://www.immunology.org
The British Society for Immunology
http://www.resus.org.uk
Resuscitation Council UK
http://www.eaaci.net
The European Academy of Allergology and Clinical
Immunology
http://www.mhra.gov.uk
The Medicines and Healthcare products Regulatory
Agency
Supporting Information
Additional Supporting information may be found in the
online version of this article:
Appendix S1 Anaesthetic Anaphylaxis Referral Form.
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any Supporting materials
supplied by the authors. Any queries (other than missing
material) should be directed to the corresponding author
for the article.
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